Journal Article
. 2020 Feb;9().
doi: 10.3389/fonc.2019.01574.

UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer

Yu-Jin Kim 1 Gyunghwa Lee 2 Jinil Han 3 Kyoung Song 4 Joon-Seok Choi 5 Yoon-La Choi 1 Young Kee Shin 2 
Affiliations
  • PMID: 32039034
  •     43 References
  •     3 citations

Abstract

We previously showed that UBE2C mRNA expression is significantly associated with poor prognosis only in patients with hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- breast cancer. In this study, we further reanalyzed the correlation between UBE2C mRNA expression and clinical outcomes in patients with HR+/HER2- breast cancer, and we investigated the molecular mechanism underlying the role of UBE2C modulation in disease progression in this subgroup of patients. Univariate and multivariate analyses showed that high UBE2C expression was associated with significantly shorter survival of breast cancer patients with pN0 and pN1 tumors but not pN2/N3 tumors (P < 0.05). In vitro functional experiments in HR+/HER2- breast cancer cells showed that UBE2C expression is a tumorigenic factor, and that estrogen upregulated UBE2C mRNA and protein by directly binding to the UBE2C promoter region. UBE2C knockdown inhibited cell proliferation by affecting cell cycle progression, and UBE2C overexpression was associated with estrogen-independent growth. UBE2C depletion markedly increased the cytotoxicity of tamoxifen by inducing apoptosis. The present findings suggest that UBE2C overexpression is correlated with relapse and promotes estrogen-dependent/independent proliferation in early HR+/HER2- breast cancer.

Keywords: HR+/HER2– breast cancer; UBE2C; apoptosis; cell cycle; estrogen; tamoxifen.

Biological determinants of endocrine resistance in breast cancer.
Elizabeth A Musgrove, Robert L Sutherland.
Nat Rev Cancer, 2009 Aug 25; 9(9). PMID: 19701242
Highly Cited. Review.
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.
Xiaoling Puyang, Craig Furman, +50 authors, Manav Korpal.
Cancer Discov, 2018 Jul 12; 8(9). PMID: 29991605
Molecular mechanisms and mode of tamoxifen resistance in breast cancer.
Shazia Ali, Mahmood Rasool, +9 authors, Mohammad Sarwar Jamal.
Bioinformation, 2017 Feb 06; 12(3). PMID: 28149048    Free PMC article.
Review.
Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells.
Livia Caizzi, Giulio Ferrero, +11 authors, Michele De Bortoli.
Proc Natl Acad Sci U S A, 2014 Mar 19; 111(13). PMID: 24639548    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.
D Loussouarn, L Campion, +6 authors, P Jézéquel.
Br J Cancer, 2009 Jun 11; 101(1). PMID: 19513072    Free PMC article.
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.
Jason S Carroll, X Shirley Liu, +10 authors, Myles Brown.
Cell, 2005 Jul 13; 122(1). PMID: 16009131
Highly Cited.
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Jinil Han, Yoon-La Choi, +11 authors, Young Kee Shin.
Breast Cancer Res Treat, 2017 Apr 15; 164(1). PMID: 28409241    Free PMC article.
High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.
Zhihua Shen, Xiaofan Jiang, +8 authors, Wei Jie.
BMC Cancer, 2013 Apr 17; 13. PMID: 23587173    Free PMC article.
Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy.
Ramón García-Escudero, Ana B Martínez-Cruz, +8 authors, Jesús M Paramio.
Mol Cancer, 2010 Jul 16; 9. PMID: 20630075    Free PMC article.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
Deadly encounter: ubiquitin meets apoptosis.
Veronika Jesenberger, Stefan Jentsch.
Nat Rev Mol Cell Biol, 2002 Feb 12; 3(2). PMID: 11836513
Review.
UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme.
Yoshiaki Okamoto, Toshinori Ozaki, +3 authors, Akira Nakagawara.
Cancer Res, 2003 Jul 23; 63(14). PMID: 12874022
Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Yanli Tan, Qixue Wang, +5 authors, Bo Zhang.
Int J Oncol, 2018 Oct 27; 54(1). PMID: 30365046    Free PMC article.
Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.
Chen-Pin Chou, Nan-Chieh Huang, +6 authors, Tsung-Hsien Chang.
PLoS One, 2014 Apr 05; 9(4). PMID: 24699941    Free PMC article.
Proteogenomics connects somatic mutations to signalling in breast cancer.
Philipp Mertins, D R Mani, +34 authors, NCI CPTAC.
Nature, 2016 Jun 03; 534(7605). PMID: 27251275    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Association of clinicopathological features with UbcH10 expression in colorectal cancer.
Shimin Chen, Yingjian Chen, +3 authors, Xianxi Liu.
J Cancer Res Clin Oncol, 2009 Sep 26; 136(3). PMID: 19779934
UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1.
Pedro Nicolau-Neto, Antonio Palumbo, +6 authors, Luis Felipe Ribeiro Pinto.
Genes (Basel), 2018 Mar 30; 9(4). PMID: 29596365    Free PMC article.
The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data.
Chao-Hua Mo, Li Gao, +4 authors, Zhen-Bo Feng.
Cancer Cell Int, 2017 Oct 13; 17. PMID: 29021715    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T C Chou, P Talalay.
Adv Enzyme Regul, 1984 Jan 01; 22. PMID: 6382953
Highly Cited.
Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.
Ze-Kun Zhao, Wen-Guang Wu, +5 authors, Ying-Bin Liu.
Tumour Biol, 2013 Jan 29; 34(3). PMID: 23355337
A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Ensel Oh, Yoon-La Choi, +3 authors, Young Kee Shin.
Breast Cancer Res Treat, 2011 Jun 15; 132(2). PMID: 21667120
Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
G J Zhang, I Kimijima, +6 authors, S Takenoshita.
Clin Cancer Res, 1999 Oct 28; 5(10). PMID: 10537367
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Massimo Cristofanilli, Nicholas C Turner, +15 authors, Dennis Slamon.
Lancet Oncol, 2016 Mar 08; 17(4). PMID: 26947331
Highly Cited.
Clinicopathological relevance of UbcH10 in breast cancer.
Takeo Fujita, Hirokuni Ikeda, +4 authors, Hiroyoshi Doihara.
Cancer Sci, 2008 Nov 29; 100(2). PMID: 19038004
Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Manfred Kaufmann, Lajos Pusztai, Biedenkopf Expert Panel Members.
Cancer, 2011 Apr 08; 117(8). PMID: 21472705
Review.
Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma.
Toshima Z Parris, Anikó Kovács, +6 authors, Khalil Helou.
Int J Cancer, 2013 Oct 12; 134(7). PMID: 24114735
Mechanisms of tamoxifen-induced apoptosis.
S Mandlekar, A N Kong.
Apoptosis, 2001 Oct 12; 6(6). PMID: 11595837
Highly Cited. Review.
Breast cancer adjuvant therapy: time to consider its time-dependent effects.
Ismail Jatoi, William F Anderson, Jong-Hyeon Jeong, Carol K Redmond.
J Clin Oncol, 2011 May 11; 29(17). PMID: 21555693    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.
Zhonglin Hao, Hui Zhang, John Cowell.
Tumour Biol, 2011 Dec 16; 33(3). PMID: 22170434
Review.
UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Won Tae Kim, Pildu Jeong, +12 authors, Wun-Jae Kim.
Oncotarget, 2016 Aug 17; 7(36). PMID: 27528424    Free PMC article.
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Pilar Eroles, Ana Bosch, J Alejandro Pérez-Fidalgo, Ana Lluch.
Cancer Treat Rev, 2011 Dec 20; 38(6). PMID: 22178455
Highly Cited. Review.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou, Suleiman Massarweh, +4 authors, Rachel Schiff.
J Natl Cancer Inst, 2004 Jun 17; 96(12). PMID: 15199112
Highly Cited.
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
T C Chou, R J Motzer, Y Tong, G J Bosl.
J Natl Cancer Inst, 1994 Oct 19; 86(20). PMID: 7932806
Highly Cited.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
Antonio Palumbo, Nathalia Meireles Da Costa, +9 authors, Luis Felipe Ribeiro Pinto.
Oncotarget, 2016 Sep 03; 7(40). PMID: 27588470    Free PMC article.
Identification and validation of genes involved in cervical tumourigenesis.
Thangarajan Rajkumar, Kesavan Sabitha, +4 authors, Ganesharaja Selvaluxmy.
BMC Cancer, 2011 Feb 23; 11. PMID: 21338529    Free PMC article.
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
A Psyrri, K T Kalogeras, +13 authors, G Fountzilas.
Ann Oncol, 2011 Nov 08; 23(6). PMID: 22056852
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort.
S P Somashekhar, Shabber Zaveri, +4 authors, Charu Bahl.
JCO Glob Oncol, 2020 Sep 09; 6. PMID: 32897733    Free PMC article.
UBE2C is a Potential Biomarker for Tumorigenesis and Prognosis in Tongue Squamous Cell Carcinoma.
Pei-Feng Liu, Chun-Feng Chen, +6 authors, Bor-Hwang Kang.
Diagnostics (Basel), 2020 Sep 10; 10(9). PMID: 32899896    Free PMC article.
The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.
Han Yeoung Lee, Seung Wan Son, +2 authors, Jong Kook Park.
Int J Mol Sci, 2021 Jan 14; 22(2). PMID: 33435156    Free PMC article.
Review.